2-(3-fluorophenyl)-3-(2-methoxyphenyl)thiazolidin-4-one | 1395434-57-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(3-fluorophenyl)-3-(2-methoxyphenyl)thiazolidin-4-one
• 英文别名: 2-(3-Fluorophenyl)-3-(2-methoxyphenyl)thiazolidin-4-one；2-(3-fluorophenyl)-3-(2-methoxyphenyl)-1,3-thiazolidin-4-one
• CAS: 1395434-57-7
• 化学式: C₁₆H₁₄FNO₂S
• 分子量: 303.357
• InChiKey: WYAOXAHARPKFRS-UHFFFAOYSA-N

物化性质

• 沸点：
  528.9±50.0 °C(Predicted)
• 密度：
  1.305±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  54.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  邻甲氧基苯胺 、 3-氟苯甲醛 在 sodium sulfate 作用下， 以 甲苯 为溶剂， 生成 2-(3-fluorophenyl)-3-(2-methoxyphenyl)thiazolidin-4-one
  参考文献：
  名称：

  10.1016/j.chembiol.2024.06.013

  摘要：

  DOI：

  10.1016/j.chembiol.2024.06.013

文献信息

• THIAZOLIDINONE COMPOUNDS AND USE THEREOF
  申请人：National Health Research Institutes

  公开号：US20170253569A1

  公开（公告）日：2017-09-07

  A pharmaceutical composition containing a compound of Formula (I) for treating an opioid receptor-associated condition. Also disclosed is a method for treating an opioid receptor-associated condition using such a compound. Further disclosed are two sets of thiazolidinone compounds of formula (I): (i) compounds each having an enantiomeric excess greater than 90% and (ii) compounds each being substituted with deuterium.

  一种含有化合物（I）的药物组合物，用于治疗与阿片受体相关的疾病。还公开了一种使用这种化合物治疗阿片受体相关疾病的方法。进一步公开了两组式（I）的噻唑烷酮化合物：（i）每种化合物的对映体过量大于90%；（ii）每种化合物被氘取代。
• Thiazolidinone compounds and use thereof
  申请人：National Health Research Institutes

  公开号：US10544113B2

  公开（公告）日：2020-01-28

  A pharmaceutical composition containing a compound of Formula (I) for treating an opioid receptor-associated condition. Also disclosed is a method for treating an opioid receptor-associated condition using such a compound. Further disclosed are two sets of thiazolidinone compounds of formula (I): (i) compounds each having an enantiomeric excess greater than 90% and (ii) compounds each being substituted with deuterium.

  一种含有用于治疗阿片受体相关疾病的式 (I) 化合物的药物组合物。还公开了一种使用此类化合物治疗阿片受体相关疾病的方法。进一步公开了两组式(I)的噻唑烷酮化合物：(i)对映体过量大于 90%的化合物和(ii)各自被氘取代的化合物。
• Optimization of 2-(3-(arylalkyl amino carbonyl) phenyl)-3-(2-methoxyphenyl)-4-thiazolidinone derivatives as potent antitumor growth and metastasis agents
  作者：Jing Wu、Linxi Yu、Feifei Yang、Jingjie Li、Peng Wang、Wenbo Zhou、Liwen Qin、Yunqi Li、Jian Luo、Zhengfang Yi、Mingyao Liu、Yihua Chen

  DOI：10.1016/j.ejmech.2014.04.068

  日期：2014.6

  A series of 2,3-diaryl-4-thiazolidinone derivatives were synthesized and evaluated for their antiproliferative properties against two well-known cancer cell lines (A549 as human lung cancer and MDA-MB-231 as human breast cancer). Structure activity relationship (SAR) analysis resulted in the discovery of 2-(3-(arylalkyl amino carbonyl)phenyl)-3-(2-methoxy-phenyl)-4-thiazolidinone derivatives with high potent inhibitory effects on the proliferation of both cancer cell lines. Furthermore, several compounds with potent antiproliferative activities displayed excellent inhibitory activities on migration with an IC50 of about 0.05 μM on MDA-MB-231 cells in two different migration assays. In particular, compound 39 was indicated to suppress tumor growth and metastasis as well as promote survival rate. Intriguingly, this series of analogs have been indicated to inhibit tumor cell proliferation through inducing cell cycle arrest. These results suggested that the new series of 2-(3-(arylalkyl amino carbonyl)phenyl)-3-(2-methoxyphenyl)-4-thiazolidinone derivatives could be regarded and developed as novel highly potential anticancer agents in the future.
• [EN] THIAZOLIDINONE COMPOUNDS AND USE THEREOF<br/>[FR] COMPOSÉS DE THIAZOLIDINONE ET LEUR UTILISATION
  申请人：SHIH CHUAN

  公开号：WO2017155910A1

  公开（公告）日：2017-09-14

  A pharmaceutical composition containing a compound of Formula (I) for treating an opioid receptor-associated condition. Also disclosed is a method for treating an opioid receptor-associated condition using such a compound. Further disclosed are two sets of thiazolidinone compounds of formula (I): (i) compounds each having an enantiomeric excess greater than 90% and (ii) compounds each being substituted with deuterium.
• 10.1016/j.chembiol.2024.06.013
  作者：Huang, Yi-Han、Lin, Shu-Yu、Ou, Li-Chin、Huang, Wei-Cheng、Chao, Po-Kuan、Chang, Yung-Chiao、Chang, Hsiao-Fu、Lee, Pin-Tse、Yeh, Teng-Kuang、Kuo, Yu-Hsien、Tien, Ya-Wen、Xi, Jing-Hua、Tao, Pao-Luh、Chen, Pin-Yuan、Chuang, Jian-Ying、Shih, Chuan、Chen, Chiung-Tong、Tung, Chun-Wei、Loh, Horace H.、Ueng, Shau-Hua、Yeh, Shiu-Hwa

  DOI：10.1016/j.chembiol.2024.06.013

  日期：——